| Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL:Case | Chemotherapy:N | Drug:Exemestane | Race:White | TIMEPOINT:3 Month | Tamoxyfen:Y | Taxane |
|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1078 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1086 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1115 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1132 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1151 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1156 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1159 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1240 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1240 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1310 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1359 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1473 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1484 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1534 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1573 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1589 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1608 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1701 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1727 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1761 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1793 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1822 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1833 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1846 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1866 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 1993 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2038 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2070 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2075 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2089 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2119 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2157 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2180 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2207 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2246 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2259 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2320 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2384 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2384 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2425 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2513 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2521 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2571 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2576 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2601 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2610 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2620 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 2744 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3070 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3104 | Peak area | Y |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3269 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3271 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3313 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3396 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3409 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 3634 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 4113 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 4128 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 4354 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 5648 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | 6054 | Peak area | N |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | Y | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase NEGATIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M-H)- | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | 1028 | Peak area | N |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | 1679 | Peak area | N |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | 3016 | Peak area | N |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | N | |
| Reversed phase POSITIVE ION MODE | N-ACETYLNEURAMINATE (CAS# 131-48-6); (M+NA)+ | Peak area | Y |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|